Beyang Therapeutics Co., Ltd.
PrivateLast Round
Series A
Aug 12, 2026
Total Funding Raised
$30M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Beyang Therapeutics Co., Ltd. is a biopharmaceutical company that develops novel therapies for ophthalmic and oncological diseases using its proprietary ExCEED drug discovery platform.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Clinical Trials, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Beyang Therapeutics Co., Ltd. Comparables
Compare Beyang Therapeutics Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| neoX Biotech | 84% | |
| MindRank | 83% | |
| HeliXon | 81% |
Beyang Therapeutics Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Aug 12, 2026 | ||||
| Seed | Feb 19, 2024 | ||||
| Pre Seed | Jul 17, 2023 |
Beyang Therapeutics Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Shanghai Healthcare Capital | Series A |
| Ming Bioventures | Pre Seed |
| YuanBio Venture Capital | Series A |
| Legend Capital | Series A |
| Root Venture Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 17, 2026
Open roles increased to 8, 200% of headcount.
- Aug 12, 2026
$30M round led by Shanghai Healthcare Capital and Legend Capital.
Recent news
Latest coverage and updates
- receives_financingAug 12, 2026
Beyang Therapeutics Co., Ltd. receives nearly $30M in an oversubscribed Series A financing round in China on Aug 12th '26, co-led by Legend Capital and Shanghai Healthcare Capital with participation from China Medical System Holdings Limited, Fenglei Capital, Shanghai Sci-Tech Innovation Center Capital, Harbor & Canton Capital, Root Venture Partners, and YuanBio Venture Capital to advance its ExCEED platform, drug pipelines, and international expansion.
Beyang Therapeutics Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Beyang Therapeutics Co., Ltd.'s valuation, stock price, and market status.
Is Beyang Therapeutics Co., Ltd. a public or private company?
Beyang Therapeutics Co., Ltd. is a private company.
What is the current stock price of Beyang Therapeutics Co., Ltd.?
Beyang Therapeutics Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks Beyang Therapeutics Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Beyang Therapeutics Co., Ltd. worth (valuation)?
Valuation information for Beyang Therapeutics Co., Ltd. is not publicly available.
Can I buy Beyang Therapeutics Co., Ltd. stock?
Beyang Therapeutics Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Beyang Therapeutics Co., Ltd.'s last funding round?
Beyang Therapeutics Co., Ltd.'s most recent funding round was Series A on August 12, 2026.
Who are the main investors in Beyang Therapeutics Co., Ltd.?
Key investors in Beyang Therapeutics Co., Ltd. include Shanghai Healthcare Capital, Ming Bioventures, Legend Capital.
Will Beyang Therapeutics Co., Ltd. IPO soon?
No public IPO plans have been announced for Beyang Therapeutics Co., Ltd..
How can I track Beyang Therapeutics Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Beyang Therapeutics Co., Ltd.'s shares on secondary markets.